Cargando…
Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations
Dominant centronuclear myopathy (CNM) is a rare form of congenital myopathy associated with a wide clinical spectrum, from severe neonatal to milder adult forms. There is no available treatment for this disease due to heterozygous mutations in the DNM2 gene encoding Dynamin 2 (DNM2). Dominant DNM2 m...
Autores principales: | Dudhal, Swati, Mekzine, Lylia, Prudhon, Bernard, Soocheta, Karishma, Cadot, Bruno, Mamchaoui, Kamel, Trochet, Delphine, Bitoun, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439966/ https://www.ncbi.nlm.nih.gov/pubmed/36090755 http://dx.doi.org/10.1016/j.omtn.2022.08.016 |
Ejemplares similares
-
Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy
por: Trochet, Delphine, et al.
Publicado: (2022) -
Allele‐specific silencing therapy for Dynamin 2‐related dominant centronuclear myopathy
por: Trochet, Delphine, et al.
Publicado: (2017) -
Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing
por: Trochet, Delphine, et al.
Publicado: (2016) -
A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target
por: Trochet, Delphine, et al.
Publicado: (2021) -
Nuclear defects in skeletal muscle from a Dynamin 2-linked centronuclear myopathy mouse model
por: Fongy, Anaïs, et al.
Publicado: (2019)